# TQB6411

Source: https://onco.cc/drugs/tqb6411/  
OnCo record `tqb6411` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TQB6411 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical in phase 2 trials for non-small-cell lung cancer and oesophageal cancer, aimed at EGFR and MET.

## Summary

TQB6411 is an antibody-drug conjugate developed by Chia Tai Tianqing Pharmaceutical. Its targets are EGFR and MET. ClinicalTrials.gov describes the intervention as: TQB6411 for Injection is administered every 21 days as a treatment cycle. TQB6411 for injection is administered every 28 days as a treatment cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in non-small-cell lung cancer and oesophageal cancer. The largest, NCT07367529, plans to enrol 465 participants with primary completion expected 2028-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: Antibody-drug conjugate directed at EGFR and MET, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of TQB6411: https://clinicaltrials.gov/search?intr=TQB6411

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [MET](https://onco.cc/targets/met/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- trials: [A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection](https://onco.cc/trials/nct07367529/), [Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer](https://onco.cc/trials/nct07367516/)

---
JSON: https://onco.cc/api/v1/entities/tqb6411.json